These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8852521)

  • 21. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent changes in pregnancy and lactation labeling: retirement of risk categories.
    Ramoz LL; Patel-Shori NM
    Pharmacotherapy; 2014; 34(4):389-95. PubMed ID: 24390829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of A Machine Learning Algorithm to Classify Drugs Of Unknown Fetal Effect.
    Boland MR; Polubriaginof F; Tatonetti NP
    Sci Rep; 2017 Oct; 7(1):12839. PubMed ID: 28993650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perception of teratogenic risk of common medicines.
    Sanz E; Gómez-López T; Martínez-Quintas MJ
    Eur J Obstet Gynecol Reprod Biol; 2001 Mar; 95(1):127-31. PubMed ID: 11267734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization of juvenile animal studies to determine the human effects and risks of environmental toxicants during postnatal developmental stages.
    Brent RL
    Birth Defects Res B Dev Reprod Toxicol; 2004 Oct; 71(5):303-20. PubMed ID: 15505806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug safety: Pregnancy rating classifications and controversies.
    Wilmer E; Chai S; Kroumpouzos G
    Clin Dermatol; 2016; 34(3):401-9. PubMed ID: 27265079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [An update in drug use during pregnancy: risk classification].
    Gallego Úbeda M; Delgado Téllez de Cepeda L; Campos Fernández de Sevilla Mde L; De Lorenzo Pinto A; Tutau Gómez F
    Farm Hosp; 2014 Jul; 38(4):364-78. PubMed ID: 25137169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The U.S. Food and Drug Adminstration (FDA) has assigned pregnancy category D to valproate.
    Peckman H
    N C Med J; 2010; 71(4):396-8. PubMed ID: 21155112
    [No Abstract]   [Full Text] [Related]  

  • 29. Human teratogens: update 2010.
    Holmes LB
    Birth Defects Res A Clin Mol Teratol; 2011 Jan; 91(1):1-7. PubMed ID: 21254353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).
    Daw JR; Mintzes B; Law MR; Hanley GE; Morgan SG
    Clin Ther; 2012 Jan; 34(1):239-249.e2. PubMed ID: 22169049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals.
    Pole M; Einarson A; Pairaudeau N; Einarson T; Koren G
    J Clin Pharmacol; 2000 Jun; 40(6):573-7. PubMed ID: 10868307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug use before and during pregnancy in Serbia.
    Odalovic M; Vezmar Kovacevic S; Ilic K; Sabo A; Tasic L
    Int J Clin Pharm; 2012 Oct; 34(5):719-27. PubMed ID: 22744842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PregTox: A Resource of Knowledge about Drug Fetal Toxicity.
    Chen Q; Gan Y; Wang K; Li Q
    Biomed Res Int; 2022; 2022():4284146. PubMed ID: 35469349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug use in pregnancy; a point to ponder!
    Sachdeva P; Patel BG; Patel BK
    Indian J Pharm Sci; 2009 Jan; 71(1):1-7. PubMed ID: 20177448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicians' Perspective of the New Pregnancy and Lactation Labeling Rule (PLLR): Results from an AAAAI/FDA Survey.
    Namazy J; Chambers C; Sahin L; Johnson T; Dinatale M; Lappin B; Schatz M
    J Allergy Clin Immunol Pract; 2020 Jun; 8(6):1947-1952. PubMed ID: 32084595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. National patterns of medication use during pregnancy.
    Lee E; Maneno MK; Smith L; Weiss SR; Zuckerman IH; Wutoh AK; Xue Z
    Pharmacoepidemiol Drug Saf; 2006 Aug; 15(8):537-45. PubMed ID: 16700083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs and Birth Defects: a knowledge database providing risk assessments based on national health registers.
    Nörby U; Källén K; Eiermann B; Korkmaz S; Winbladh B; Gustafsson LL
    Eur J Clin Pharmacol; 2013 Apr; 69(4):889-99. PubMed ID: 23011015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation.
    Brent RL
    Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):906-18. PubMed ID: 16206282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug use in pregnancy: how to avoid problems.
    Rao JM; Arulappu R
    Drugs; 1981 Nov; 22(5):409-14. PubMed ID: 6120825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of using the health smart card vs. CPOE reminder system on the prescribing practices of non-obstetric physicians during outpatient visits for pregnant women in Taiwan.
    Long AJ; Chang P
    Int J Med Inform; 2012 Sep; 81(9):605-11. PubMed ID: 22705085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.